Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate

Completed

Conditions: attention and concentration
Cognitive deficits
Problems with memory
10012303

Registration Number: NL-OMON44348

Lead Sponsor: Anatomie en Neurowetenschappen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 75

Inclusion Criteria

To participate in the MRI part of the study:
- Clinically definite Relapsing Remitting or Secondary Progressive Multiple sclerosis
- Sufficient visual acuity and motor performance to perform the MRI task
- Between 18 and 60 years of age;To participate in the PET-part of the study:
- Minimum hemoglobin values of 8 g/dl for men and 7 g/dl for women

Exclusion Criteria

For the MRI-part of the study:
- MR contraindications
- Neurological and/or psychiatric disorders (other than MS; e.g. depression, schizophrenia, alcohol or drug abuse)
- For MS patients: the use of corticosteroids in the 4 weeks prior to inclusion. ;For the PET-part of the study:
- benzodiazepine use or other drug use that affects the benzodiazepine site on the GABA receptor system (e.g. imidazopyridines, pyrazolopryimidines en cyclopyrrolones) 6 weeks or less before the start of the study.
- The use of GHB (gamma-hydroxybutyrate)
- In the case of pregnancy or breastfeeding
- Insufficient haemoglobin value values as discussed in the inclusion criteria.
- (a history of) significant cardiac disease
- exposure to previous radiation leading to an annual cumulative dose of more than 10mSv

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome parameters are the concentrations of GABA (expressed as<br /><br>GABA to creatine ratio) and glutamate (in mM) in the right hippocampus and<br /><br>thalamus and whole- brain as well as regional GABAA receptor density (in<br /><br>pmol/ml) in MS patients and controls.</p><br>

Secondary Outcome Measures